Background. Safe and efficacious modalities of perioperative analgesia are essential for enhanced recovery after surgery. Truncal nerve blocks are one potential adjunct for analgesia of the abdominal wall, and in recent years their popularity has increased. Transversus abdominis plane block (TAPB) and rectus sheath block (RSB) have been shown to reduce morphine consumption and improve pain relief after abdominal surgery. These blocks typically require large volumes of local anaesthetic (LA). We aimed to synthesize studies evaluating systemic concentrations of LA after perioperative TAP and RSB to enhance our understanding of systemic LA absorption and the risk of systemic toxicity.
problem. As surgical techniques change and length of inpatient stay decreases, it is important to offer safe and reliable methods of analgesia that may be delivered in both hospital and outpatient settings.
Regional anaesthesia has become an important addition to multimodal regimens of analgesia for postoperative pain. The block of pain impulses by local anaesthetic (LA) provides effective pain relief for abdominal surgery, either on its own or as part of a multimodal analgesic regimen. 2 With the development of ultrasound imaging techniques that enable precise target identification, truncal blocks, such as transversus abdominis plane block (TAPB) or rectus sheath block (RBS), are becoming popular after abdominal surgery. 3 4 Previous clinical trials have
shown that the addition of truncal blocks to multimodal regimens of analgesia significantly reduces pain and opioid consumption after surgery. [5] [6] [7] Transversus abdominis plane block and RSB are compartmental blocks, which require large volumes of LA to optimize the spread within a fascial plane towards a target nerve or group of nerves. 8 Despite the increasing interest in truncal blocks, little is known about systemic concentrations of LA after truncal nerve block. The large doses of LA required raise the potential issue of LA systemic toxicity. Local anaesthetic systemic toxicity is characterized by central nervous system and cardiac instability ranging from dizziness to seizures, and from mild arrhythmia to cardiovascular collapse and death, respectively. 9 10 Systemic concentrations of LA are correlated with the vascularity of the tissue, LA pharmacodynamic properties and effects of potential additives, and patient conditions such as pregnancy or sepsis.
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After a single bolus injection of LA, peak concentrations are greatest after intrapleural or intercostal administration followed in decreasing order by caudal, epidural, brachial plexus, and lower limb blocks. 12 The systemic absorption of LA after epidural and brachial plexus applications has been well characterized and discussed in the literature. 13 14 The aim of this review was to synthesize data from studies assessing perioperative LA systemic concentrations after single bolus TAPB and RSB and define the plasma concentrations to be expected.
Methods
A systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement where possible. 15 Two authors (J.R., J.T.) independently performed a series of electronic searches of four databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and PubMed). With the assistance of a subject librarian, the first author (J.R.) collated a list of keywords and search terms to incorporate into strategies adapted for each database. The search terms combined local anaesthetics, anterior abdominal wall blocks, systemic concentrations, and pharmacokinetics of local anaesthetics. Language limitation was not applied. Truncated search terms were used to increase the hit rate. Search results were downloaded and managed with RefWorks citation management software (ProQuest LLC, Ann Arbor, MI, USA).
Study selection
Abstracts were screened and full-text papers obtained to identify primary research studies reporting serum concentrations of LA agents used in ultrasound-guided (USG) anterior abdominal wall blocks (TAPB and RSB) in adult patients for any indication.
The primary outcome of interest was serum concentrations of LA agents in the first 24 h after surgery. All human clinical trials, whether randomized, quasi-randomized, or non-randomized, that primarily evaluated serum concentrations of LA agents after TAPB or RSB were included. Exclusion criteria included studies that did not evaluate serum concentrations of LA agents, studies on infants and children (<18 yr of age), and those articles for which full-text publications were not available (e.g. conference abstracts). Two reviewers (J.R., J.T.) independently performed the searches and examined titles and abstracts to exclude irrelevant reports and produce a list of studies for full-text review in an iterative process. Any disagreement over inclusion or exclusion was discussed with the senior author (A.G.H.) and a consensus reached. Additional articles and abstracts were retrieved by manually examining reference lists of relevant publications. The last search was performed on July 16, 2016.
Data abstraction
Data extraction was performed independently by the first author and entered in predesigned electronic tables. Tables recorded patient characteristics, operative characteristics, LA dose and type, and LA serum concentrations, including pharmacokinetic parameters (C max and T max ), where C max refers to the maximal serum concentration that a drug achieves and T max refers to the time at which C max is observed. Data were reported as the mean (SD) where possible, and only recorded if stated in the text, tables, graphs, or figures of the articles. The median score was used as an estimate of the mean where the latter was not reported. Standard deviation measures were attempted based on the methods described in the Cochrane Handbook of Systematic Reviews of Interventions, where attempts to contact authors for clarification were unsuccessful (up to two emails). 16 Variations in the timing of outcome measures, procedure type, and study cohorts limited meaningful synthesis of the data. Pharmacokinetic modelling was not attempted because of study heterogeneity and differences in LA detection method and anaesthetic regimens. The data are therefore presented as a narrative review.
Assessment of risk of bias
Two reviewers (J.R., J.T.) independently applied the NewcastleOttawa Scale (NOS), which assesses the methodological quality of non-randomized aspects of study design, including patient selection, comparability of study groups, and assessment of outcomes. 17 The tool uses a scoring system with a maximum of nine stars, and studies that achieve five or more stars are considered high quality.
Results
The literature search identified 206 records in the initial database search. A PRISMA flow diagram for the systematic review is presented in Fig. 1 . Fifteen clinical studies met the inclusion criteria and were included in the review. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Three studies were excluded, where two studies were abstracts from conference proceedings, and multiple LA applications were used in the remaining study (Table 3 ). The majority of the included studies used ropivacaine as their chosen LA agent. 18-23 26 28-31 One study used lidocaine, 24 and three studies used levobupivacaine. 25 27 32 Among 381 participants included for analysis in all 15 studies, there were 33 reported instances where systemic LA concentrations exceeded toxic threshold parameters (as defined by the publication authors). Of these instances, three patients exhibited subjective symptoms of mild LA systemic toxicity. 21 Symptoms were limited to perioral and tongue paraesthesia, a metallic taste, and slurred speech. No instances of severe neurotoxicity (seizures) or persistent cardiovascular instability were observed.
Transversus abdominis plane block
Eleven studies measured systemic concentrations of LA agents after bilateral USG TAPB (Table 2 ). Abdominal or pelvic surgery was performed in eight studies, [18] [19] [20] [21] [22] [23] [24] [25] while in the remaining three studies participants were healthy volunteers who did not undergo any surgery. [26] [27] [28] Eight of the 11 studies used ropivacaine. 18-23 26 28 Peak systemic concentrations of ropivacaine were dose dependent, with mean doses of ropivacaine ranging from 50 to 200 mg, and weight-based doses ranging from 1.9 to 4.2 mg kg À1 . Four studies concurrently measured free concentrations of ropivacaine. 18-20 22 Mean pharmacokinetic C max and
T max variables for each study are shown in Table 2 . Twenty-nine instances among all included TAPB studies exceeded systemic concentration thresholds for ropivacaine as defined by the respective study authors. [18] [19] [20] [21] There is some variation in the LA systemic thresholds used in the included studies, as shown in Table 2 . The highest mean individual peak systemic concentration of ropivacaine observed was in a study by Griffiths and colleagues, 20 who measured concentrations in pregnant women undergoing Caesarean section. This was the only study where participants (n¼3) reported instances of mild systemic toxicity with symptoms of perioral and tongue paraesthesia, a metallic taste, and slurred speech. One study used lidocaine in patients undergoing laparoscopic surgery. 24 Individual C max values ranged from 2.7 to 5.5 mg ml À1 (Table 2) . No adverse effects were reported. The effect on the systemic absorption of ropivacaine, lidocaine, or levobupivacaine after bilateral USG TAPB with the addition of epinephrine was not assessed. A graphical representation of LA systemic absorption after bilateral TAPB in several of the studies is shown in Fig. 2 .
Rectus sheath block
Four studies measured systemic concentrations of LA, of which three used ropivacaine and one used levobupivacaine. [29] [30] [31] [32] One study exclusively measured LA systemic concentrations after bilateral USG RSB. 29 The remaining studies compared changes in the systemic concentrations of LA between patients receiving bilateral USG RSB and TAPB. [30] [31] [32] Mean peak concentration (C max ) and T max were lower in the RSB groups compared with the TAPB groups. Dose-dependent increases in mean peak systemic concentrations were also observed and are shown in Table 3 .
Additives
The effect of epinephrine on LA absorption was assessed in one study. 30 Although no significant findings were observed in the RSB group, the addition of epinephrine to ropivacaine after TAPB led to a decreased C max and delayed T max . There were no reported instances of LA systemic toxicity despite predefined toxic thresholds being exceeded in three patients. The systemic absorption of LA after bilateral USG RSB is depicted in Fig. 3 .
Discussion
This review identified 15 studies investigating systemic concentrations of LA after TAPB and RSB. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] It is the first systematic review to collate primary studies assessing the safety of LA after anterior abdominal wall blocks. Although a significant number of patients in the included trials exceeded potentially toxic thresholds (33 of 381 patients) of LA as defined by previous clinical trials and case studies, only three patients reported mild symptoms of LA systemic toxicity. This highlights the somewhat arbitrary nature of typical LA systemic toxic thresholds. Furthermore, we note that even using widely accepted LA dosages, TAPB and RSB can lead to plasma concentrations in excess of predefined thresholds of toxicity. However, all instances observed in the present study were associated with only mild neurotoxicity, and no cardiovascular instability was observed. Local anaesthetics inhibit the central nervous system in a dose-dependent manner through blockage of sodium channel function and cessation of action potential propagation. 36 They also have anti-inflammatory, anti-thrombotic, anti-microbial, anti-adhesion-forming, and neuroprotective properties. 37 The process of plasma binding reduces pharmacologically active free concentrations of LA and attenuates crossing of the blood-brain barrier and binding of cardiac channels, causing central nervous system or cardiac toxicity, respectively. 40 Thresholds of LA systemic toxicity have been defined in older studies but not cross-validated for truncal blocks or patients with different conditions. Ropivacaine possesses intrinsic vasoconstrictive properties and is thought to have a safer side-effect profile. 41 42 This narrative is reflected by the predominant selection of ropivacaine for truncal blocks among the included studies in this review. A study of volunteers receiving titrated i.v. infusions of ropivacaine until occurrence of clinical signs of central nervous system toxicity showed symptom onset at a mean total venous concentration of 2.2 mg ml À1 and an unbound concentration of 0.15 mg ml À1 . 9 Given the paucity of information to suggest otherwise, these ropivacaine thresholds are generally accepted. This is somewhat evident in the use of these parameters in the majority of the included studies using ropivacaine for TAPB or RSB. Single bolus anterior abdominal wall blocks were assessed in healthy participants undergoing abdominal or pelvic surgery. In response to the stress of surgery, studies have observed increased concentrations of a 1 -acid glycoprotein that in turn lower free concentrations of LA.
11 43 Latzke and colleagues 28 measured total and free concentrations of ropivacaine after bilateral USG TAPB in healthy volunteers. Two studies included in this review assessed patients undergoing laparotomy in a similar manner. 20 22 In comparison, Latzke and colleagues 28 observed higher free concentrations of ropivacaine and a notably lower C max . Another study in healthy volunteers also demonstrated a lower C max after concomitant classic TAPB and upper intercostal block despite higher volumes of ropivacaine.
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This occurrence highlights the potential physiological differences that can exist in surgical patients and how this can influence the resorption kinetics of LA. The TAPB aims to produce anaesthesia and analgesia of the lower abdominal wall below the umbilicus. 44 Generally, a large volume of LA is injected in the neurovascular plane between the transversus abdominis (deep) and internal oblique muscles of the abdominal wall to block segmental thoraco-abdominal nerves. Systemic toxic thresholds of LA were predominantly exceeded in patients who received bilateral USG TAPB. 18-21 24 Symptomatic patients were reported in a single study that prospectively assessed healthy women undergoing elective Caesarean section for LA systemic toxicity after bilateral TAPB. 20 Mean body weight of symptomatic patients was greater compared with asymptomatic patients, resulting in higher mean doses of ropivacaine. Importantly, pregnancy is a peculiar physiological state, which results in reduced concentrations of a 1 -acid glycoprotein. 45 This increases the likelihood of systemic toxicity as a result of high circulating concentrations of free LA. 46 These phenomena are more than likely to have contributed to the high mean total C max and instances of LA systemic toxicity. The addition of a vasopressor, such as epinephrine, to LA solution can reduce peak concentrations of LA and delay systemic absorption. 47 Interestingly, Kitayama and colleagues observed this effect with epinephrine only in the TAPB group and not in the RSB group. 30 In general, the RSB groups appeared to have delayed T max when compared with the TAPB groups. Despite this, no significant differences of C max were observed between various truncal blocks using the same LA. The RSB is achieved by LA agent administrated to block the terminal branches of the ninth, 10th, and 11th intercostal nerves and Anatomical studies demonstrate the relationship between the location of LA administration and the desired region of anaesthesia, where exposure to large vascular surface areas provides ideal conditions for rapid LA systemic absorption. 49 Therefore, delayed C max and ineffective vasopressor activity after bilateral RSB could be attributed to a relatively avascular fascial plane, possibly accounting for a more rapid systemic absorption of LA observed after TAPB. Traditionally, LA amounts were high and administration was highly unselective because of blind techniques that may have led to block of adjacent nerves. Since the initial description of truncal blocks, the introduction of ultrasound guidance has provided the advantage of reliably depositing LA under realtime imaging. 6 This has in effect improved block success rates and minimized the potential for harm. Numerous modifications to block techniques have seen the evolution from single injection blind techniques to improved USG techniques. 7 50 51 With further advances of interest, including surgical or anaesthetic placement of wound catheters for LA infusions, enhancing our understanding of LA systemic concentrations after abdominal wall block is important. 52 This systematic review has a number of limitations. First, as a result of the lack of individually reported data, pharmacodynamic or pharmacokinetic modelling was not possible. Study heterogeneity was present, and the lack of adequate pharmacological attention in the presented studies meant that meaningful synthesis was limited. Another limitation was the low number of RSB studies. This made it difficult to make robust comparisons between the profiles of LA agents as applied to the two different anterior abdominal wall block studies.
In conclusion, LA use in anterior abdominal wall blocks can lead to detectable systemic concentrations that exceed commonly accepted thresholds of LA systemic toxicity. Dosing regimens for truncal blocks have been tested only in healthy subjects. In the absence of patient studies determining safe doses for LA in truncal blocks, providers should take LA dose, patient co-morbidities/conditions, and site of injection into account whenever performing TAPB or RSB, and remain vigilant for systemic toxicity at all times. Under these premises, our study shows that the site of injection in TAPB and RSB is associated with a relatively slow absorption, and therefore, the safety profile can be considered good.
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